ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors

Core Insights - Oryzon Genomics has received a patent grant from the Japanese Patent Office for its application related to combinations of iadademstat for cancer therapy, which is a significant step in enhancing its patent portfolio [1][2][3] Patent Protection - The granted patent is expected to remain effective until at least 2040, excluding any potential extensions, securing Oryzon's intellectual property in Europe, Japan, Australia, and Russia [2] - Oryzon is actively pursuing corresponding patent applications in other countries to further strengthen its global patent coverage [2] Clinical Development - Iadademstat is being evaluated in combination with immune checkpoint inhibitors, specifically atezolizumab and durvalumab, for the treatment of small cell lung cancer (SCLC) in an ongoing Phase I/II trial sponsored by the U.S. National Cancer Institute [3] - The trial is being conducted at over 30 clinical sites across the U.S., including prestigious institutions like Memorial Sloan Kettering Cancer Center and Johns Hopkins [3] Company Overview - Founded in 2000, Oryzon Genomics is a clinical-stage biopharmaceutical company based in Barcelona, Spain, focusing on epigenetics and personalized medicine in oncology and CNS disorders [4] - The company has a robust clinical portfolio, including two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [4] Iadademstat Details - Iadademstat (ORY-1001) is a selective inhibitor of the epigenetic enzyme LSD1, showing promising results in hematologic cancers and is currently in various clinical trials for conditions such as acute myeloid leukemia (AML) and small cell lung cancer [5][6] - The drug has demonstrated safety and preliminary efficacy in multiple trials, including a Phase IIa trial in combination with azacitidine for elderly AML patients [5]